DelveInsight’s ‘Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Spinal Muscular Atrophy in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of SMA from 2017 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (France, Germany, Italy, Spain and the United Kingdom)
Study Period: 2017-2027
SMA- Disease Understanding and Treatment Algorithm
The DelveInsight Spinal Muscular Atrophy market report gives the thorough understanding of SMA by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for SMA in the US, Europe and Japan.
The SMA epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population of SMA and Diagnosed Type-Specific cases of SMA (Type 1, 2, 3 & 4) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2027.
According to DelveInsight, the prevalent population of SMA was estimated to be 38,900 [7MM] in 2017.
SMA Drug Chapters
This segment of the SMA report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Spinraza is the only approved drug for the treatment of SMA. The market of Spinraza has shown high revenue and patient acceptance in launch year, however high price of the drug and reimbursement issues are hampering the growth of Spinraza. Even after the approval of Spinraza there are numerous unmet needs of the market and to counter such demands many companies are working rigorously to bring better affordable therapy to the SMA market.
Detailed chapters for all the upcoming therapies i.e., AVXS-101 (Avexis), CK-2127107 (Cytokinetics Inc.), RG7916 (Hoffman-La Roche), Olesoxime (Hoffman-La Roche), LMI070 (Novartis Pharmaceuticals) etc., have been covered in the report.
SMA Market Outlook
The SMA market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Spinal Muscular Atrophy (SMA) was estimated to be USD 825 Million in 2017, and is expected to increase at a CAGR of XX% from 2017-2027.
SMA Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2027. The analysis covers market uptake by drugs and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
SMA Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
SMA Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analysed Market
• Key Cross Competition
SMA Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the SMA market
- Organize sales and marketing efforts by identifying the best opportunities for SMA market
- To understand the future market competition in the SMA market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook